Coronary sinus narrowing safe for treating refractory angina: Interim data from REDUCER-I study

REDUCER-I is a multicentre, non-randomized observational study. The participants had refractory angina pectoris Canadian Cardiovascular Society (CCS) class II-IV and were treated with Reducer implantation.

The study demonstrated the following findings:

• In the first 228 patients (81% male, 68.3±9.6 years), the procedural success rate was 99%, with only one adjudicated possible procedural or device-related MACE.
• Mean CCS class decreased from 2.8±0.6 at baseline to 1.8±0.7 at two years.
• Improvement in ≥1 CCS class was seen in 82%, and≥2 CCS classes in 31% of patients at two years.
• At baseline, 70% of the cohort were reported to be in CCS class III-IV; this portion was reduced to 15% at follow-up.
• An improvement in additional measured parameters of functional class and quality of life was also observed.

The safety profile of therapy was confirmed in patients with refractory angina, as established in the interim results from the ongoing REDUCER-I study.

"The results also showed a sustained improvement in angina severity and quality of life for up to two years," the researchers wrote.

Reference:

The study titled "Coronary sinus narrowing for the treatment of refractory angina: a multicentre prospective open-label clinical study (the REDUCER-I study)" was published in the journal EuroIntervention. DOI: 10.4244/EIJ-D-20-00873